Cancer Treatments
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
56
NCT05617755
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
Phase: Phase 1
Role: Lead Sponsor
Start: Nov 29, 2022
Completion: Feb 28, 2027
NCT06245915
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
Phase: Phase 1/2
Start: Feb 26, 2024
Completion: Jun 30, 2028
Loading map...